Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 25, 2026DrugsOpen Access

Autoimmune Bullous Diseases: Therapeutic Update

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMichael KasperkiewiczNBN. van BeekESEnno Schmidt

Discussion

Loading...

Member takes

Overview

Review summarizes recent clinical trials and new therapies for autoimmune blistering diseases, indicating a need for effective treatments.

Key Points

  • This review aims to summarize recent advancements and current treatment options for autoimmune blistering diseases (AIBDs).
  • Review of randomized controlled trials (RCTs) for pemphigus and bullous pemphigoid.
  • Analysis of new therapeutic agents like dupilumab and efgartigimod.
  • Overview of national and international treatment guidelines.
  • Recent approval of dupilumab for bullous pemphigoid signifies treatment progress.
  • Immunoadsorption and rilzabrutinib show promise for pemphigus.
  • Lack of RCTs for mucous membrane pemphigoid highlights unmet medical needs.

Cite This Study

Kasperkiewicz et al. (2026) studied this question.

synapsesocial.com/papers/699e918df5123be5ed04f25fhttps://doi.org/10.1007/s40265-026-02292-3
View Full Paper
Ask AI
Bookmark
Share